-- 根據週三提交給上海證券交易所的文件，資本證券（SHA:601136）第一季歸屬於股東的淨利潤年增30%，從去年同期的1.511億元人民幣增至1.967億元。 每股盈餘較去年同期成長17%，從0.06元人民幣增至0.07元。 營業收入較去年同期成長31%，從去年同期的4.323億元增加至5.655億元。 該證券公司股價收盤上漲近5%。
Related Articles
Equities
RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk
Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TBN
Asia
Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
$HKG:2607$SHA:601607
Mining & Metals
CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY
$GIB-A.TO